Finerenone is a non-steroidal mineralocorticoid receptor antagonist used as an active pharmaceutical ingredient. It is supplied as a pharmaceutical raw material for the manufacturing of medications indicated to reduce the risk of kidney function decline, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes, as well as for heart failure with reduced ejection fraction.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1050477-27-4
4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid
pharmaceutical intermediate
(S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylic Acid
pharmaceutical intermediate
(4R)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxylic acid
pharmaceutical intermediate
5-Desethoxy,-5-Methoxy-Finerenone
pharmaceutical raw material
Dolutegravir
pharmaceutical raw material
Dolutegravir sodium
pharmaceutical raw material
7-methyl-2-(2,2,3,3-tetradeuteriocyclopropyl)-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
pharmaceutical raw material
Tetrabutylammonium acetate
pharmaceutical raw material
4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
BTBHLEZXCOBLCY-UHFFFAOYSA-N
CCOC1=NC=C(C2=C1C(C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C